Cargando…

Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease

BACKGROUND: A recent trial involving predominantly Caucasian subjects with Parkinson Disease (PD) showed switching overnight from an oral dopaminergic agonist to the rotigotine patch was well tolerated without loss of efficacy. However, no such data have been generated for Korean patients. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Han-Joon, Jeon, Beom S, Lee, Won Yong, Lee, Myoung Chong, Kim, Jae Woo, Kim, Jong-Min, Ahn, Tae-Beom, Cho, Jinwhan, Chung, Sun Ju, Grieger, Frank, Whitesides, John, Boroojerdi, Babak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166898/ https://www.ncbi.nlm.nih.gov/pubmed/21831297 http://dx.doi.org/10.1186/1471-2377-11-100

Ejemplares similares

Transdermal rotigotine for the perioperative management of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2010)

A Study for Expanding Application Sites for Rotigotine Transdermal Patch
por: Kujirai, Hitoshi, et al.
Publicado: (2020)

Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
por: Talty, Ronan, et al.
Publicado: (2022)

Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects
por: Cawello, Willi, et al.
Publicado: (2013)

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis
por: Giladi, Nir, et al.
Publicado: (2016)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation
por: Ogawa, Takashi, et al.
Publicado: (2018)

Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?
por: Rosa-Grilo, Miguel, et al.
Publicado: (2017)

Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study
por: Kassubek, Jan, et al.
Publicado: (2014)

Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
por: Kim, Jong-Min, et al.
Publicado: (2015)

Rotigotine Transdermal Patch in Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Zhou, Chang-Qing, et al.
Publicado: (2013)

Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2016)

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
por: LeWitt, Peter A., et al.
Publicado: (2012)

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis
por: LeWitt, Peter A., et al.
Publicado: (2016)

Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease
por: Yun, Ji Young, et al.
Publicado: (2013)

Rotigotine transdermal system: a short review
por: Bunten, Sabine, et al.
Publicado: (2006)

Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
por: Högl, Birgit, et al.
Publicado: (2010)

Impulse control disorder related behaviours during long‐term rotigotine treatment: a post hoc analysis
por: Antonini, A., et al.
Publicado: (2016)

Transdermal rotigotine for the perioperative management of restless legs syndrome
por: Högl, Birgit, et al.
Publicado: (2012)

Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism
por: Moretti, Davide Vito, et al.
Publicado: (2014)

Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience
por: Raeder, Vanessa, et al.
Publicado: (2021)

Efficacy and Safety of Rotigotine Transdermal Patch on Neuropsychiatric Symptoms of Parkinson's Disease: An Updated Meta-Analysis and Systematic Review
por: Yan, Junqiang, et al.
Publicado: (2021)

Delirious episode secondary to rotigotine: the psychotic patch
por: Andreo Vidal, M. A., et al.
Publicado: (2023)

Transdermal iontophoresis patch with reverse electrodialysis
por: Lee, Joon, et al.
Publicado: (2017)

Sleepiness and Depression in Parkinson’s Disease Patients Treated with Ropinirole and Levodopa
por: Kang, Suk Yun, et al.
Publicado: (2017)

Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT
por: Bauer, Axel, et al.
Publicado: (2016)

Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists
por: Ikeda, Ken, et al.
Publicado: (2016)

Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, pLacebo-Controlled Study (RECOVER)
por: Trenkwalder, Claudia, et al.
Publicado: (2011)

Treatment of Gait Ignition Failure with Ropinirole
por: Cohen-Oram, Alexis N., et al.
Publicado: (2014)

Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report
por: Imbriani, Paola, et al.
Publicado: (2017)

Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers
por: Kim, Yo Han, et al.
Publicado: (2015)

Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study
por: Pagonabarraga, Javier, et al.
Publicado: (2015)

Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
por: Kesayan, Tigran, et al.
Publicado: (2015)

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
por: Han, Hyun Jeong, et al.
Publicado: (2011)

Dropped head sign induced by transdermal application of the dopamine agonist rotigotine in parkinsonian syndrome: a case report
por: Dohm, Christoph P, et al.
Publicado: (2013)

Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations [Corrigendum]
Publicado: (2016)

Preventive effect of a heparinoid-containing product on the application site reaction of the rotigotine transdermal patch in Parkinson’s disease: A pilot randomized clinical trial (the SkinHeRo study)
por: Koh, Jinsoo, et al.
Publicado: (2021)

Stimuli-responsive transdermal microneedle patches
por: Makvandi, Pooyan, et al.
Publicado: (2021)

Ropinirole for the treatment of restless legs syndrome
por: Kushida, Clete A
Publicado: (2006)

Update on ropinirole in the treatment of Parkinson’s disease
por: Shill, Holly A, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_3j2ujm4jnt28r0335ar0d43non